Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Differential Expression of Adhesion Molecule Receptors May Influence Bone Marrow Microenvironment-Mediated Protection of Leukemia-Initiating Cells (LICs) in Infant MLL- rearranged ( MLL- R) Acute Lymphoblastic Leukemia (ALL)

Edward Allan R. Sison, MD, Amos S. Gaikwad, PhD, Gaye Jenkins, Terzah M. Horton, MD PhD, Patrick Brown, MD, Michele S. Redell, MD PhD

Blood (2016) 128 (22): 1585.

https://doi.org/10.1182/blood.V128.22.1585.1585

Published: 2016

Journal Articles

A Novel STAT3 Inhibitor Has Potent Activity in Preclinical Models of Acute Myeloid Leukemia That Incorporate the Stromal Environment

Michael J Krueger, BS, Matthew Minus, BS, Wei Liu, PhD, Xin Long, PhD, Alexandra M. Stevens, MD, Mikhail I. Kolosov, BS, Edward Allan R. Sison, MD, David John Tweardy, MD, Zachary T. Ball, PhD, Michele S. Redell, MD PhD

Blood (2015) 126 (23): 569.

https://doi.org/10.1182/blood.V126.23.569.569

Published: 2015

Journal Articles

POL5551, a Novel and Potent CXCR4 Antagonist, Enhances Sensitivity to Chemotherapy in an in Vivo Model of High-Risk (HR) Pediatric Acute Lymphoblastic Leukemia (ALL)

Edward Allan R. Sison, MD, Daniel Magoon, BS, Li Li, PhD, Barbara Romagnoli, PhD, Garry Douglas, PhD, Gerald Tuffin, PharmD/PhD, Johann Zimmermann, PhD, Patrick Brown, MD

Blood (2014) 124 (21): 3707.

https://doi.org/10.1182/blood.V124.21.3707.3707

Published: 2014

Journal Articles

Chemosensitization and Mobilization Of AML/ALL/MDS With Plerixafor (AMD 3100), a CXCR4 Antagonist: A Phase I Study Of Plerixafor + Cytarabine and Etoposide In Pediatric Patients With Acute Leukemia and MDS

Todd Michael Cooper, Sharyn D. Baker, PharmD, PhD, Jennifer Direnzo, Tanya M. Trippett, Lia Gore, MD, Aru Narendran, MD, PhD, Keith J. August, M.D., M.Sc., Michael J. Absalon, MD, PhD, Jessica Boklan, MD, Jessica Pollard, MD, Daniel Magoon, Edward Allan R. Sison, MD, Patrick Brown, MD

Blood (2013) 122 (21): 2680.

https://doi.org/10.1182/blood.V122.21.2680.2680

Published: 2013

Journal Articles

Extended Exposure To The CXCR4 Inhibitor Plerixafor May Lead To Enhanced Microenvironment Interactions in Acute Lymphoblastic Leukemia (ALL)

Edward Allan R. Sison, MD, Daniel Magoon, Patrick Brown, MD

Blood (2013) 122 (21): 1295.

https://doi.org/10.1182/blood.V122.21.1295.1295

Published: 2013

Journal Articles

The Novel CXCR4 Antagonist POL5551 Decreases Surface CXCR4 (s-CXCR4) Expression, Inhibits Chemotaxis, and Enhances Chemosensitivity in Acute Lymphoblastic Leukemia (ALL)

Edward Allan R. Sison, MD, Daniel Magoon, Eric Chevalier, PhD, Klaus Dembowsky, MD, PhD, Patrick Brown, MD

Blood (2012) 120 (21): 780.

https://doi.org/10.1182/blood.V120.21.780.780

Published: 2012

Journal Articles

Leukemogenic WT1 Mutations Increase Proliferation by Accelerating Cell Entry Into S-Phase, and Synergize with FLT3/ITD Mutations to Enhance These Aberrant Cell Cycle Effects

Colleen E. Annesley, MD, Rachel E. Rau, MD, Gregory McCarty, Daniel Magoon, Edward Allan R. Sison, MD, David Loeb, MD, PhD, Patrick A. Brown, MD

Blood (2011) 118 (21): 2437.

https://doi.org/10.1182/blood.V118.21.2437.2437

Published: 2011

Journal Articles

Chemotherapy-Induced CXCR4 Modulation Predicts the In Vivo Efficacy of Plerixafor As a Chemosensitizer in Acute Leukemia

Edward Allan R. Sison, MD, Daniel Magoon, Li Li, PhD, Rachel E. Rau, MD, Colleen E. Annesley, MD, Donald Small, MD, PhD, Patrick A. Brown, MD

Blood (2011) 118 (21): 1410.

https://doi.org/10.1182/blood.V118.21.1410.1410

Published: 2011

Journal Articles

Upregulation of Surface CXCR4 In Response to Chemotherapy Confers a Stromal-Mediated Survival Advantage In Acute Leukemia

Edward Allan R. Sison, MD, Emily McIntyre, Daniel Magoon, Patrick Brown, MD

Blood (2010) 116 (21): 2734.

https://doi.org/10.1182/blood.V116.21.2734.2734

Published: 2010

NARROW

Differential Expression of Adhesion Molecule Receptors May Influence Bone Marrow Microenvironment-Mediated Protection of Leukemia-Initiating Cells (LICs) in Infant MLL- rearranged ( MLL- R) Acute Lymphoblastic Leukemia (ALL)

A Novel STAT3 Inhibitor Has Potent Activity in Preclinical Models of Acute Myeloid Leukemia That Incorporate the Stromal Environment

POL5551, a Novel and Potent CXCR4 Antagonist, Enhances Sensitivity to Chemotherapy in an in Vivo Model of High-Risk (HR) Pediatric Acute Lymphoblastic Leukemia (ALL)

Chemosensitization and Mobilization Of AML/ALL/MDS With Plerixafor (AMD 3100), a CXCR4 Antagonist: A Phase I Study Of Plerixafor + Cytarabine and Etoposide In Pediatric Patients With Acute Leukemia and MDS

Extended Exposure To The CXCR4 Inhibitor Plerixafor May Lead To Enhanced Microenvironment Interactions in Acute Lymphoblastic Leukemia (ALL)

The Novel CXCR4 Antagonist POL5551 Decreases Surface CXCR4 (s-CXCR4) Expression, Inhibits Chemotaxis, and Enhances Chemosensitivity in Acute Lymphoblastic Leukemia (ALL)

Leukemogenic WT1 Mutations Increase Proliferation by Accelerating Cell Entry Into S-Phase, and Synergize with FLT3/ITD Mutations to Enhance These Aberrant Cell Cycle Effects

Chemotherapy-Induced CXCR4 Modulation Predicts the In Vivo Efficacy of Plerixafor As a Chemosensitizer in Acute Leukemia

Upregulation of Surface CXCR4 In Response to Chemotherapy Confers a Stromal-Mediated Survival Advantage In Acute Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only